CBIO CRESCENT BIOPHARMA INC.

Crescent Biopharma to Present at September Investor Conferences

Crescent Biopharma to Present at September Investor Conferences

WALTHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in September:

  • Cantor Global Healthcare Conference 2025, fireside chat on Thursday, September 4, 2025, at 1:00 p.m. ET in New York.

  • Morgan Stanley 23rd Annual Global Healthcare Conference, fireside chat on Monday, September 8, 2025, at 5:35 p.m. ET in New York.

A live webcast of each presentation will be available in the Investors section of the Company's website at , and a replay will be accessible for 90 days.

About Crescent Biopharma

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit  and follow the Company on  and 

Contact

Amy Reilly

Chief Communications Officer



617-465-0586



EN
28/08/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CRESCENT BIOPHARMA INC.

 PRESS RELEASE

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 45,675 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive ...

Geoffrey Von Der Ahe ... (+2)
  • Geoffrey Von Der Ahe
  • Robert Driscoll
 PRESS RELEASE

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial...

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights Established partnership with Kelun-Biotech expanding pipeline and accelerating combination strategy with CR-001, PD-1 x VEGF bispecific antibody, and multiple ADCs ASCEND Phase 1/2 global clinical trial underway to evaluate CR-001 in advanced solid tumors with three additional clinical trials across the portfolio expected to initiate in 2026 Completed $185 million private placement, supporting several key clinical data readouts beginning in Q1 2027 and providing expected cash run...

 PRESS RELEASE

Crescent Biopharma to Present at March Investor Conferences

Crescent Biopharma to Present at March Investor Conferences WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in March: TD Cowen 46th Annual Health Care Conference, fireside chat on Monday, March 2, 2026 at 3:50 p.m. ET in Boston.Leerink Partners 2026 Global Healthcare Conference, fireside chat on Wednesday, March 11, 2026 at 8:40 a....

 PRESS RELEASE

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 24,600 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incen...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch